Asset Details
Do you wish to reserve the book?
Long‐term efficacy (at and beyond 1 year) of gastric peroral endoscopic myotomy for refractory gastroparesis: A systematic review and meta‐analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long‐term efficacy (at and beyond 1 year) of gastric peroral endoscopic myotomy for refractory gastroparesis: A systematic review and meta‐analysis
Do you wish to request the book?
Long‐term efficacy (at and beyond 1 year) of gastric peroral endoscopic myotomy for refractory gastroparesis: A systematic review and meta‐analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long‐term efficacy (at and beyond 1 year) of gastric peroral endoscopic myotomy for refractory gastroparesis: A systematic review and meta‐analysis
2025
Overview
Introduction Although gastric peroral endoscopic myotomy (G‐POEM) has shown substantial efficacy in patients with medically refractory gastroparesis (GP), comprehensive long‐term data on its effectiveness are lacking. Methods We conducted a systematic review and meta‐analysis including observational studies assessing long‐term efficacy after G‐POEM in patients with refractory GP. Our primary outcome was the pooled rate of clinical success 1‐year after G‐POEM. Secondary outcomes included clinical success at 2 and 3 years and the rate of adverse events according to the American Society for Gastrointestinal Endoscopy classification. Results Thirteen studies, involving 952 patients with refractory GP undergoing G‐POEM, were eligible. The pooled 1 year‐clinical success was 0.72 (95% confidence interval [CI]: 0.56, 0.85, I2 = 94.9%). The clinical success was 0.67 (95% CI: 0.47, 0.97, I2 = 95.8%) when considering only studies defining success as 1 point decrease in Gastroparesis Cardinal Symptoms Index score and at least 25% decrease in two subscales. For patients who had 1‐year success, the pooled clinical success at 2 and 3 years were 0.71 (95% CI: 0.45, 0.92, I2 = 94.9%) and 0.58 (95% CI: 0.19, 0.92, I2 = 97.1%), respectively. The pooled rate of adverse events was 0.08 (95% CI: 0.06, 0.10, I2 = 0%). Conclusion G‐POEM is associated with successful outcomes in about 70% of treated cases after 1 year, with durable long‐term effects lasting up to 3 years. In the future, new uniform outcome definitions and strict patient selection criteria are warranted to delineate G‐POEM outcomes more accurately.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
